-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$42.202121.05% Upside
RAPT Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover RAPT Therapeutics, Inc.?
RAPT Therapeutics, Inc. has been rated by research analysts at Guggenheim, Wells Fargo, Piper Sandler, Goldman Sachs, Capital One Financial in the past 90 days.